Table 2 Interim PET-directed ongoing... | American Society of Hematology

Table 2

Interim PET-directed ongoing studies in advanced-stage HL

Reference	Phase	Sample	Stage	End point	Pre-iPET CHT	iPET^{− arm(s)}	iPET^{+ arm}	Group/title/NCT no.	End year
53	II	450	IIB-IV	3-y PFS	ABVD × 2	ABVD × 4	escBEACOPP × 4	GITIL/HD0607	2012
							stdBEACOPP × 4	00795613
54	II	230	III-IV	2-y PFS	ABVD × 2	ABVD × 2	escBEACOPP × 6	SWOG/S0816	2012
								00822120
55	III	798	III-IV or IIB†	5-y PFS	escBEACOPP × 2	ABVD × 4 (experimental arm)	escBEACOPP × 4 (standard and experimental arms)‡	GELA/AHL 2011	2016
						escBEACOPP × 4 (standard arm)‡		01358747
56	III	1200	II^β-IV	3-y PFS	ABVD × 2	ABVD × 4 or AVD × 4	escBEACOPP × 4	CR-UK/RATHL	2012
								00678327
57	III	1500	IIB-IV	5-y PFS	escBEACOPP × 2	escBEACOPP × 6 or	escBEACOPP × 6 or	GHSG/HD18	2012
						escBEACOPP × 2	escBEACOPP × 6 + rituximab	00515554
58	III	300	IIB-IV	2-y PFS	ABVD × 2	ABVD × 4^Ω	IGEV × 4 + ASCT	FIL/ HD0801	2014
								00784537
59	II	660*	III-IV^0-2	5-y EFS	ABVD × 2	ABVD × 4	escBEACOPP × 2 + 00392314	RHC/NA	2016
							escBEACOPP × 2 + INRT^PET4−
			III-IV^3-7		escBEACOPP × 2	ABVD × 4	escBEACOPP × 2 +
							escBEACOPP × 2 + INRT^PET4−

Reference	Phase	Sample	Stage	End point	Pre-iPET CHT	iPET^{− arm(s)}	iPET^{+ arm}	Group/title/NCT no.	End year
53	II	450	IIB-IV	3-y PFS	ABVD × 2	ABVD × 4	escBEACOPP × 4	GITIL/HD0607	2012
							stdBEACOPP × 4	00795613
54	II	230	III-IV	2-y PFS	ABVD × 2	ABVD × 2	escBEACOPP × 6	SWOG/S0816	2012
								00822120
55	III	798	III-IV or IIB†	5-y PFS	escBEACOPP × 2	ABVD × 4 (experimental arm)	escBEACOPP × 4 (standard and experimental arms)‡	GELA/AHL 2011	2016
						escBEACOPP × 4 (standard arm)‡		01358747
56	III	1200	II^β-IV	3-y PFS	ABVD × 2	ABVD × 4 or AVD × 4	escBEACOPP × 4	CR-UK/RATHL	2012
								00678327
57	III	1500	IIB-IV	5-y PFS	escBEACOPP × 2	escBEACOPP × 6 or	escBEACOPP × 6 or	GHSG/HD18	2012
						escBEACOPP × 2	escBEACOPP × 6 + rituximab	00515554
58	III	300	IIB-IV	2-y PFS	ABVD × 2	ABVD × 4^Ω	IGEV × 4 + ASCT	FIL/ HD0801	2014
								00784537
59	II	660*	III-IV^0-2	5-y EFS	ABVD × 2	ABVD × 4	escBEACOPP × 2 + 00392314	RHC/NA	2016
							escBEACOPP × 2 + INRT^PET4−
			III-IV^3-7		escBEACOPP × 2	ABVD × 4	escBEACOPP × 2 +
							escBEACOPP × 2 + INRT^PET4−

std indicates standard. See Table 1 for other abbreviations.

This study has 4 arms involving both early- and advanced-stage HL (thus mentioned in Table 1 as well); 0-2, patients with IPS 0-2; 3-4, patients with IPS 3-7.

†

High-risk IIB stage, β, stage IIB, or IIA disease with adverse features, Ω, PET2-negative patients randomized to IFRT versus no IFRT based on initial bulky disease.

‡

For patients with a positive PET-4 (interim PET scan after 4 cycles of chemotherapy) a rescue treatment is followed with HDT/ASCT.

View Large

This Feature Is Available To Subscribers Only